NHS in England Approves Life-Extending Breast Cancer Drug Enhertu Following Years of Campaigning

Hundreds of women in England diagnosed with an incurable form of breast cancer will now be able to receive a life-extending medication on the NHS, concluding a protracted campaign after health authorities previously ruled the treatment too costly.

The pharmaceutical treatment, known commercially as Enhertu, has been cleared for prescription to patients living with HER2-low metastatic breast cancer. Clinical evidence indicates that the drug can grant individuals an average of nearly seven additional months of life, with certain patients experiencing survival extensions reaching up to three years. Approximately 1,000 women each year in England are expected to be eligible for the therapy.

Medical practitioners across England were authorized to begin prescribing the therapy on Thursday. Devolved administrations have experienced differing timelines, with Scotland having provided access on its public health service since 2023, and Wales anticipated to adopt similar guidance in the near future. However, the ruling does not automatically extend to Northern Ireland. Beyond the UK, the treatment has already been routinely accessible across 26 other European nations.

The breakthrough follows years of intense advocacy by patient groups and charitable organizations. The National Institute for Health and Care Excellence (NICE), the body responsible for assessing the cost-effectiveness of medical treatments in England, had initially turned down the drug in 2024 on the grounds that it did not represent sufficient value for money for the public health budget.

Welcoming the latest development, Health Secretary Yvette Cooper characterized the medication as potentially life-changing. She noted that the revised recommendation would finally allow NHS patients to experience its therapeutic benefits, describing the outcome as a direct testament to the persistence of charities and individuals who campaigned relentlessly for wider access.

Despite the positive outcome, health advocates emphasized that the prolonged delay had carried a heavy human toll. Claire Rowney, the chief executive of the charity Breast Cancer Now, acknowledged the immense relief of finally securing approval but stressed that the victory was overshadowed by the reality that thousands of eligible women had been denied access in the intervening period, with many dying before the decision was reversed.

Among those directly affected is 51-year-old Kate Wills, who is living with stage four HER2-low metastatic breast cancer that has spread to her lungs and bones. Balancing a demanding career alongside family life as a mother and wife, Wills had described the ongoing unavailability of a viable life-extending treatment as extraordinarily painful.

Upon learning that Enhertu would be funded on the NHS, Wills expressed profound relief, explaining that maintaining optimism while navigating a terminal diagnosis is exceptionally difficult. The approval has fundamentally reshaped her personal outlook, shifting her aspirations from simply surviving to see her youngest child complete secondary school to envisioning major future milestones, including watching her teenage and young adult children marry.

Nevertheless, Wills noted that the resolution remains bittersweet, thinking immediately of fellow patients who did not survive long enough to benefit from the policy reversal. Among them was campaigner Jeannie Ambrose, who died in January after spending significant portions of her remaining life lobbying for the drug to be approved, speaking out publicly about her frustration at having to spend precious time fighting administrative barriers rather than being with family.

The eventual decision by NICE to reverse its position did not stem from substantial price reductions by the pharmaceutical companies producing the treatment, Daiichi Sankyo and AstraZeneca. Instead, the shift was predominantly facilitated by broader governmental economic adjustments, specifically an international trade agreement with the United States in which the UK committed to raising its total expenditure on medicines by 25 percent.

Following that broader commitment, NICE modified its standard economic evaluation framework. The watchdog raised its upper spending threshold for a Quality-Adjusted Life Year (QALY)—the standard measurement used to calculate how much the NHS should pay for an additional year of good-quality life provided by a treatment—from £30,000 to £35,000.

In addition to adjusting the financial threshold, NICE implemented an updated and more nuanced methodology for evaluating patient quality of life at the end of August. These combined technical and budgetary revisions provided the necessary leeway to reverse the earlier rejection and approve the drug for general NHS use.

Both Daiichi Sankyo and AstraZeneca expressed support for the revised recommendation. AstraZeneca emphasized the need for stronger cross-sector collaboration across the broader healthcare framework to guarantee that patients face fewer delays in securing cutting-edge therapies in the future.

Charity leaders have reiterated calls for comprehensive structural reforms to prevent similar impasses. Rowney urged government ministers, NICE, NHS England, and the pharmaceutical sector to address flaws in the appraisal apparatus so that individuals diagnosed with incurable conditions are never again forced to expend their remaining time campaigning for accessible treatments.

Helen Knight, the director of medicines evaluation at NICE, confirmed her satisfaction that a commercial solution had ultimately been secured, enabling the life-extending treatment to finally reach the NHS patients who require it.